CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery - PubMed (original) (raw)
. 2009 Sep 1;15(17):5518-27.
doi: 10.1158/1078-0432.CCR-09-0151. Epub 2009 Aug 25.
Yang Xu, Bin Yu, Jian Zhou, Jia-Chu Li, Shuang-Jian Qiu, Ying-Hong Shi, Xiao-Ying Wang, Zhi Dai, Guo-Ming Shi, Bin Wu, Li-Ming Wu, Guo-Huan Yang, Bo-Heng Zhang, Wen-Xin Qin, Jia Fan
Affiliations
- PMID: 19706825
- DOI: 10.1158/1078-0432.CCR-09-0151
CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery
Xin-Rong Yang et al. Clin Cancer Res. 2009.
Abstract
Purpose: To investigate the role of CD24 in tumor invasion and prognostic significance in hepatocellular carcinoma (HCC).
Experimental design: CD24 expression was measured in stepwise metastatic HCC cell lines, tumor, peritumoral tissues, and normal liver tissues by quantitative real-time PCR and Western blot. The role of CD24 in HCC was investigated by CD24 depletion using small interfering RNA. Tumor tissue microarrays of 314 HCC patients who underwent resection between 1997 and 2000 were used to detect expression of CD24, beta-catenin, and proliferating cell nuclear antigen. Prognostic significance was assessed using Kaplan-Meier survival estimates and log-rank tests.
Results: CD24 was overexpressed in the highly metastatic HCC cell line and in tumor tissues of patients with recurrent HCC. Depletion of CD24 caused a notable decrease in cell proliferation, migration, and invasiveness in vitro. Univariate and multivariate analyses revealed that CD24 was a significant predictor for overall survival and relapse-free survival. CD24 expression was correlated with poor prognosis independent of alpha-fetoprotein, tumor-node-metastasis stage, and Edmondson stage. High CD24 expression was significantly associated with cytoplasmic and nuclear accumulation of beta-catenin (P = 0.023), high tumor proliferative status (P = 0.018), and diffused intrahepatic recurrence and distant metastasis (P = 0.026). Adjuvant transcatheter arterial chemoembolization after surgery reduced the rate of early recurrence (<or=1 year) in CD24(+) HCC patients (P = 0.024) but had no significant effect in CD24(-) patients (P = 0.284).
Conclusions: Overexpression of CD24 in HCC was associated with high invasiveness and metastatic potential, high tumor proliferation status, and activation of the Wnt/beta-catenin pathway. CD24 may be a novel predictor for poor prognosis of HCC patients after surgery.
Similar articles
- Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection.
Yang XR, Xu Y, Shi GM, Fan J, Zhou J, Ji Y, Sun HC, Qiu SJ, Yu B, Gao Q, He YZ, Qin WZ, Chen RX, Yang GH, Wu B, Lu Q, Wu ZQ, Tang ZY. Yang XR, et al. Clin Cancer Res. 2008 Jun 15;14(12):3850-9. doi: 10.1158/1078-0432.CCR-07-4338. Clin Cancer Res. 2008. PMID: 18559605 - CD24: a novel cancer biomarker in laryngeal squamous cell carcinoma.
Shi Y, Gong HL, Zhou L, Tian J, Wang Y. Shi Y, et al. ORL J Otorhinolaryngol Relat Spec. 2012;74(2):78-85. doi: 10.1159/000335584. Epub 2012 Feb 21. ORL J Otorhinolaryngol Relat Spec. 2012. PMID: 22354323 - Elevated expression of DKK1 is associated with cytoplasmic/nuclear beta-catenin accumulation and poor prognosis in hepatocellular carcinomas.
Yu B, Yang X, Xu Y, Yao G, Shu H, Lin B, Hood L, Wang H, Yang S, Gu J, Fan J, Qin W. Yu B, et al. J Hepatol. 2009 May;50(5):948-57. doi: 10.1016/j.jhep.2008.11.020. Epub 2009 Jan 9. J Hepatol. 2009. PMID: 19303159 - Surgical treatment of hepatocellular carcinoma and related basic research with special reference to recurrence and metastasis.
Tang Z, Zhou X, Lin Z, Yang B, Ma Z, Ye S, Wu Z, Fan J, Liu Y, Liu K, Qin L, Tian J, Sun H, He B, Xia J, Qiu S, Zhou J. Tang Z, et al. Chin Med J (Engl). 1999 Oct;112(10):887-91. Chin Med J (Engl). 1999. PMID: 11717970 Review. - Recent advances in tumor markers of human hepatocellular carcinoma.
Yoon SK. Yoon SK. Intervirology. 2008;51 Suppl 1:34-41. doi: 10.1159/000122596. Epub 2008 Jun 10. Intervirology. 2008. PMID: 18544946 Review.
Cited by
- Emerging Immune Checkpoint Molecules on Cancer Cells: CD24 and CD200.
Moon SY, Han M, Ryu G, Shin SA, Lee JH, Lee CS. Moon SY, et al. Int J Mol Sci. 2023 Oct 11;24(20):15072. doi: 10.3390/ijms242015072. Int J Mol Sci. 2023. PMID: 37894750 Free PMC article. Review. - The functions and roles of C2H2 zinc finger proteins in hepatocellular carcinoma.
Li Q, Tan G, Wu F. Li Q, et al. Front Physiol. 2023 Jun 29;14:1129889. doi: 10.3389/fphys.2023.1129889. eCollection 2023. Front Physiol. 2023. PMID: 37457025 Free PMC article. Review. - CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer.
Yang P, Yu F, Yao Z, Ding X, Xu H, Zhang J. Yang P, et al. Cancer Immunol Immunother. 2023 Oct;72(10):3191-3202. doi: 10.1007/s00262-023-03491-7. Epub 2023 Jul 7. Cancer Immunol Immunother. 2023. PMID: 37418008 Free PMC article. - Recent advances of three-dimensional bioprinting technology in hepato-pancreato-biliary cancer models.
Zhuang X, Deng G, Wu X, Xie J, Li D, Peng S, Tang D, Zhou G. Zhuang X, et al. Front Oncol. 2023 Apr 28;13:1143600. doi: 10.3389/fonc.2023.1143600. eCollection 2023. Front Oncol. 2023. PMID: 37188191 Free PMC article. Review. - Emerging phagocytosis checkpoints in cancer immunotherapy.
Liu Y, Wang Y, Yang Y, Weng L, Wu Q, Zhang J, Zhao P, Fang L, Shi Y, Wang P. Liu Y, et al. Signal Transduct Target Ther. 2023 Mar 7;8(1):104. doi: 10.1038/s41392-023-01365-z. Signal Transduct Target Ther. 2023. PMID: 36882399 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous